HRG and prostate cancer: [145] LMAb3 is an anti-HER3 antibody that can reverse HRG-mediated acquired resistance to anti-HER2 agents in ovarian cancer.[146] SGP1 is an anti-HER3 antibody that impairs HRG binding to HER3 and enhances antitumor effects when combined with trastuzumab.[147] Ab6 is an anti-HER3 antibody that, when combined with trastuzumab, reverses resistance to PI3K inhibitors in prostate cancer cells.[148]